TransMedics Group, Inc.
Company Stats
- Market Cap
- $2.9B
- as of Sep 30, 2026
- Shares Outstanding
- 34.7M
- Free Float
- 93.1%
Income Statement
- Revenue
- $605.5M
- Operating Income
- $108.6M
- Net Income
- $190.3M
- EBITDA
- $135.8M
- Revenue Growth, 3Y
- 86.4%
- FCF Margin, 3Y Avg
- -21.5%
- FCF Margin, Worst Year
- -68.2%
Cash Flow
- Free Cash Flow
- $133.6M
- FCF Yield
- 4.6%
- Owner FCF Yield
- 3.3%
Returns & Capital
- SBC, 3Y Avg
- $30.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $605.5M | $133.6M | 22.1% |
| FY2024 | $441.5M | -$80.9M | -18.3% |
| FY2023 | $241.6M | -$164.9M | -68.2% |
| FY2022 | $93.5M | -$57.7M | -61.8% |
| FY2021 | $31.4M | -$32.4M | -103.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back